Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration

Feng Sheng Wang, Re Wen Wu, Wei Shiung Lain, Tsai Chen Tsai, Yu Shan Chen, Yi Chih Sun, Huei Jing Ke, Jui Chen Li, Jaulang Hwang, Jih Yang Ko

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Sclerostin (SOST) is a Wnt signaling inhibitor detrimental to osteogenic differentiation and bone mineral acquisition. While control of SOST action delays the pathogenesis of skeletal disorders, the effects of SOST vaccination on the estrogen deficiency-induced bone deterioration remain elusive. In this study, we generated a SOST-Fc fusion protein which was composed of a SOST peptide Pro-Asn-Ala-Ile-Gly along with an IgG Fc fragment. SOST-Fc vaccination increased serum anti-SOST antibody levels and reduced serum SOST concentrations in mice. In vitro, anti-SOST serum attenuated the SOST-induced inhibition of osteogenic gene expression in osteoblast cultures. Administration with SOST-Fc increased serum levels of bone formation marker osteocalcin and alleviated the ovariectomy escalation of serum resorption markers CTX-1 and TRAP5b concentrations. It remarkably lessened the estrogen deficiency-mediated deterioration of bone mineral density, morphometric characteristics of trabecular bone, and mechanical strength of femurs and lumbar spines. The SOST-Fc-treated skeletal tissue exhibited moderate responses to the adverse actions of ovariectomy to bone mineral accretion, osteoclast surface, trabecular separation, and fatty marrow histopathology. SOST-Fc treatment increased serum osteoclast-inhibitory factor osteoprotegrin levels in conjunction with strong Wnt3a, β-catenin, and TCF4 immunostaining in osteoblasts, whereas it weakened the estrogen deficiency enhancement of osteoclast-promoting factor receptor activator of nuclear factor-κB ligand. Taken together, blockade of SOST action by SOST-Fc vaccination sustains Wnt signaling, which harmonizes bone mineral accretion and resorption reactions and thereby ameliorates ovariectomy-induced bone loss. This study highlights SOST-Fc fusion protein as a new molecular therapeutic potential for preventing from osteoporotic disorders.

Original languageEnglish
Pages (from-to)24-34
Number of pages11
JournalBone
Volume112
DOIs
Publication statusPublished - Jul 1 2018
Externally publishedYes

Fingerprint

Estrogens
Vaccination
Bone and Bones
Ovariectomy
Osteoclasts
Minerals
Serum
Osteoblasts
Immunoglobulin Fc Fragments
Catenins
Osteocalcin
Cytoplasmic and Nuclear Receptors
Osteogenesis
Bone Density
Femur
Anti-Idiotypic Antibodies
Proteins
Spine
Immunoglobulin G
Biomarkers

Keywords

  • Estrogen deficiency
  • Fc fusion protein
  • Osteoporosis
  • Sclerostin
  • Vaccination

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Wang, F. S., Wu, R. W., Lain, W. S., Tsai, T. C., Chen, Y. S., Sun, Y. C., ... Ko, J. Y. (2018). Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration. Bone, 112, 24-34. https://doi.org/10.1016/j.bone.2018.04.007

Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration. / Wang, Feng Sheng; Wu, Re Wen; Lain, Wei Shiung; Tsai, Tsai Chen; Chen, Yu Shan; Sun, Yi Chih; Ke, Huei Jing; Li, Jui Chen; Hwang, Jaulang; Ko, Jih Yang.

In: Bone, Vol. 112, 01.07.2018, p. 24-34.

Research output: Contribution to journalArticle

Wang, FS, Wu, RW, Lain, WS, Tsai, TC, Chen, YS, Sun, YC, Ke, HJ, Li, JC, Hwang, J & Ko, JY 2018, 'Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration', Bone, vol. 112, pp. 24-34. https://doi.org/10.1016/j.bone.2018.04.007
Wang, Feng Sheng ; Wu, Re Wen ; Lain, Wei Shiung ; Tsai, Tsai Chen ; Chen, Yu Shan ; Sun, Yi Chih ; Ke, Huei Jing ; Li, Jui Chen ; Hwang, Jaulang ; Ko, Jih Yang. / Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration. In: Bone. 2018 ; Vol. 112. pp. 24-34.
@article{3b2fbf3cd138408da4c9537f3fdf12b4,
title = "Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration",
abstract = "Sclerostin (SOST) is a Wnt signaling inhibitor detrimental to osteogenic differentiation and bone mineral acquisition. While control of SOST action delays the pathogenesis of skeletal disorders, the effects of SOST vaccination on the estrogen deficiency-induced bone deterioration remain elusive. In this study, we generated a SOST-Fc fusion protein which was composed of a SOST peptide Pro-Asn-Ala-Ile-Gly along with an IgG Fc fragment. SOST-Fc vaccination increased serum anti-SOST antibody levels and reduced serum SOST concentrations in mice. In vitro, anti-SOST serum attenuated the SOST-induced inhibition of osteogenic gene expression in osteoblast cultures. Administration with SOST-Fc increased serum levels of bone formation marker osteocalcin and alleviated the ovariectomy escalation of serum resorption markers CTX-1 and TRAP5b concentrations. It remarkably lessened the estrogen deficiency-mediated deterioration of bone mineral density, morphometric characteristics of trabecular bone, and mechanical strength of femurs and lumbar spines. The SOST-Fc-treated skeletal tissue exhibited moderate responses to the adverse actions of ovariectomy to bone mineral accretion, osteoclast surface, trabecular separation, and fatty marrow histopathology. SOST-Fc treatment increased serum osteoclast-inhibitory factor osteoprotegrin levels in conjunction with strong Wnt3a, β-catenin, and TCF4 immunostaining in osteoblasts, whereas it weakened the estrogen deficiency enhancement of osteoclast-promoting factor receptor activator of nuclear factor-κB ligand. Taken together, blockade of SOST action by SOST-Fc vaccination sustains Wnt signaling, which harmonizes bone mineral accretion and resorption reactions and thereby ameliorates ovariectomy-induced bone loss. This study highlights SOST-Fc fusion protein as a new molecular therapeutic potential for preventing from osteoporotic disorders.",
keywords = "Estrogen deficiency, Fc fusion protein, Osteoporosis, Sclerostin, Vaccination",
author = "Wang, {Feng Sheng} and Wu, {Re Wen} and Lain, {Wei Shiung} and Tsai, {Tsai Chen} and Chen, {Yu Shan} and Sun, {Yi Chih} and Ke, {Huei Jing} and Li, {Jui Chen} and Jaulang Hwang and Ko, {Jih Yang}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.bone.2018.04.007",
language = "English",
volume = "112",
pages = "24--34",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration

AU - Wang, Feng Sheng

AU - Wu, Re Wen

AU - Lain, Wei Shiung

AU - Tsai, Tsai Chen

AU - Chen, Yu Shan

AU - Sun, Yi Chih

AU - Ke, Huei Jing

AU - Li, Jui Chen

AU - Hwang, Jaulang

AU - Ko, Jih Yang

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Sclerostin (SOST) is a Wnt signaling inhibitor detrimental to osteogenic differentiation and bone mineral acquisition. While control of SOST action delays the pathogenesis of skeletal disorders, the effects of SOST vaccination on the estrogen deficiency-induced bone deterioration remain elusive. In this study, we generated a SOST-Fc fusion protein which was composed of a SOST peptide Pro-Asn-Ala-Ile-Gly along with an IgG Fc fragment. SOST-Fc vaccination increased serum anti-SOST antibody levels and reduced serum SOST concentrations in mice. In vitro, anti-SOST serum attenuated the SOST-induced inhibition of osteogenic gene expression in osteoblast cultures. Administration with SOST-Fc increased serum levels of bone formation marker osteocalcin and alleviated the ovariectomy escalation of serum resorption markers CTX-1 and TRAP5b concentrations. It remarkably lessened the estrogen deficiency-mediated deterioration of bone mineral density, morphometric characteristics of trabecular bone, and mechanical strength of femurs and lumbar spines. The SOST-Fc-treated skeletal tissue exhibited moderate responses to the adverse actions of ovariectomy to bone mineral accretion, osteoclast surface, trabecular separation, and fatty marrow histopathology. SOST-Fc treatment increased serum osteoclast-inhibitory factor osteoprotegrin levels in conjunction with strong Wnt3a, β-catenin, and TCF4 immunostaining in osteoblasts, whereas it weakened the estrogen deficiency enhancement of osteoclast-promoting factor receptor activator of nuclear factor-κB ligand. Taken together, blockade of SOST action by SOST-Fc vaccination sustains Wnt signaling, which harmonizes bone mineral accretion and resorption reactions and thereby ameliorates ovariectomy-induced bone loss. This study highlights SOST-Fc fusion protein as a new molecular therapeutic potential for preventing from osteoporotic disorders.

AB - Sclerostin (SOST) is a Wnt signaling inhibitor detrimental to osteogenic differentiation and bone mineral acquisition. While control of SOST action delays the pathogenesis of skeletal disorders, the effects of SOST vaccination on the estrogen deficiency-induced bone deterioration remain elusive. In this study, we generated a SOST-Fc fusion protein which was composed of a SOST peptide Pro-Asn-Ala-Ile-Gly along with an IgG Fc fragment. SOST-Fc vaccination increased serum anti-SOST antibody levels and reduced serum SOST concentrations in mice. In vitro, anti-SOST serum attenuated the SOST-induced inhibition of osteogenic gene expression in osteoblast cultures. Administration with SOST-Fc increased serum levels of bone formation marker osteocalcin and alleviated the ovariectomy escalation of serum resorption markers CTX-1 and TRAP5b concentrations. It remarkably lessened the estrogen deficiency-mediated deterioration of bone mineral density, morphometric characteristics of trabecular bone, and mechanical strength of femurs and lumbar spines. The SOST-Fc-treated skeletal tissue exhibited moderate responses to the adverse actions of ovariectomy to bone mineral accretion, osteoclast surface, trabecular separation, and fatty marrow histopathology. SOST-Fc treatment increased serum osteoclast-inhibitory factor osteoprotegrin levels in conjunction with strong Wnt3a, β-catenin, and TCF4 immunostaining in osteoblasts, whereas it weakened the estrogen deficiency enhancement of osteoclast-promoting factor receptor activator of nuclear factor-κB ligand. Taken together, blockade of SOST action by SOST-Fc vaccination sustains Wnt signaling, which harmonizes bone mineral accretion and resorption reactions and thereby ameliorates ovariectomy-induced bone loss. This study highlights SOST-Fc fusion protein as a new molecular therapeutic potential for preventing from osteoporotic disorders.

KW - Estrogen deficiency

KW - Fc fusion protein

KW - Osteoporosis

KW - Sclerostin

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85045461197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045461197&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2018.04.007

DO - 10.1016/j.bone.2018.04.007

M3 - Article

VL - 112

SP - 24

EP - 34

JO - Bone

JF - Bone

SN - 8756-3282

ER -